01—Abstract
Summary
Summary of the 8-K filed January 14, 2025. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. furnished this Form 8-K under Item 7.01 (Regulation FD) ahead of a presentation at the 43rd Annual J.P.
Morgan Healthcare Conference on January 14, 2025, at approximately 5:15 p.m. Eastern time. The company posted a slide presentation that offers a preliminary assessment of its 2025 outlook.
It expects 2025 revenue to decline organically in a similar range to its estimated 2024 decline, with constrained spending from global biopharma clients due to restructuring programs and pipeline reprioritization. It expects non-GAAP operating margin to be modestly below the estimated 2024 level, as cost savings can protect margin but cannot fully offset lower revenue. Full 2025 guidance is planned for release with fourth-quarter 2024 results in mid-February 2025.
In its Discovery and Safety Assessment (DSA) segment, biotech demand key performance indicators stabilized in 2024 and gradually improved year over year. Global biopharma demand stabilized in the second half of 2024 after meaningful deterioration during the second quarter, and the company expects current trends to persist into 2025 and continue to pressure year-over-year growth rates. DSA pricing is expected to be a revenue headwind in 2025.
The filing flags material pressure in the contract development and manufacturing organization (CDMO) business. A cell therapy client has reevaluated its manufacturing network and notified the company that it will terminate its commercial agreement, and the company expects lower commercial revenue from another cell therapy client. The company states that it is currently assessing the recoverability of goodwill and long-lived assets for a potential impairment.
02—Key points
Key Highlights
- Expects 2025 revenue to decline organically in a similar range as the estimated 2024 decline, driven by constrained spending from global biopharma clients.
- Expects 2025 non-GAAP operating margin to be modestly below the estimated 2024 level; restructuring and efficiency savings are expected to protect margin but cannot fully offset lower revenue.
- Lower commercial CDMO revenue is expected to reduce consolidated revenue growth by approximately 1% in 2025; site consolidation is a revenue headwind of approximately 0.5%, and FX is expected to be a headwind of more than 1% to reported revenue.
- A cell therapy CDMO client has notified the company it will terminate its commercial agreement to use another long-time CDMO partner, and lower commercial revenue is also expected from another cell therapy client.
- The company is assessing the recoverability of goodwill and long-lived assets in the CDMO business for a potential impairment.
- Biotech DSA demand KPIs stabilized in 2024 and gradually improved year over year, while global biopharma demand stabilized in the second half of 2024 after deterioration in the second quarter.
- Full 2025 guidance is planned for release with fourth-quarter 2024 financial results in mid-February 2025.
03—Questions
Frequently Asked Questions
What is Charles River's preliminary 2025 revenue outlook?
The company expects 2025 revenue to decline organically in a similar range as estimated in 2024. DSA client demand is expected to remain relatively consistent with second-half 2024 trends, and DSA pricing is expected to be a headwind.
How is the company's profitability expected to change in 2025?
Non-GAAP operating margin is expected to be modestly below the estimated 2024 level. Cost savings from restructuring and efficiency initiatives are intended to protect margin but cannot fully offset lower revenue.
What is driving the problems in the CDMO business?
A cell therapy client has reevaluated its manufacturing network and will terminate its commercial agreement with the company, and lower commercial revenue is also expected from another cell therapy client. The company notes that cell and gene therapy client demand is not as robust as at the time of its 2021 acquisition of the business, though it sees long-term growth opportunities and a pipeline of early-stage biotech clients.
Could the company record an impairment charge?
Yes, possibly. The company states that, because of the CDMO business challenges, it is currently assessing the recoverability of goodwill and long-lived assets for a potential impairment.
When will investors get full 2025 guidance?
The company plans to issue full 2025 guidance with its fourth-quarter 2024 financial results in mid-February 2025.
04—Continue